Ozempic Gastroparesis Settlement: Key Factors in Claim Valuation

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Targeted Risk Awareness

For decades, the general health and science information landscape has provided the public with foundational knowledge about human physiology, medication safety, and the importance of informed medical decision-making. This legacy of accessible, neutral education has empowered individuals to understand how treatments interact with the body and to recognize when adverse effects may arise. Within this broad context, the public has become increasingly aware that certain widely prescribed medications carry specific, serious risks that require careful monitoring and, in some cases, legal recourse. As the domain of mass production continues to expand the availability of pharmaceutical products, the focus naturally shifts from general awareness to the real-world consequences of exposure. In particular, the widespread use of GLP-1 receptor agonists has introduced a new occupational and clinical concern: the potential for delayed gastric emptying and its complications. This transition from broad health literacy to a targeted exposure risk underscores the need for a structured evaluation of factors that influence claims related to such outcomes. Understanding these valuation factors is essential for stakeholders navigating the intersection of pharmaceutical benefit and harm.

Ozempic and Gastroparesis: The Clinical Connection

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its pharmacological action slows gastric emptying, a mechanism that can lead to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, resulting in symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and bloating. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. In the context of Ozempic use, the onset of gastroparesis symptoms often correlates with dose escalation or prolonged treatment. The FDA Adverse Event Reporting System (FAERS) database lists "impaired gastric emptying" as a frequently reported adverse event associated with Ozempic, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This signal is supported by clinical trial data showing that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, compared to 32.7% for Ozempic 0.5 mg and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than placebo patients (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Evidence and Risk Anchors for Claims

The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor activation, which inhibits gastric motility and delays gastric emptying. This effect is dose-dependent and can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The FAERS data showing 2,693 reports of impaired gastric emptying (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC) underscores the clinical significance of this adverse effect. Risk anchors for settlement considerations include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but does not explicitly list gastroparesis as a contraindication or a specific warning. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation due to these reactions was higher in the Ozempic groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the term "gastroparesis" is not used in the label, which may affect the adequacy of warnings for patients and prescribers. Settlement-related considerations for affected patients include the severity and duration of gastroparesis symptoms, the need for medical interventions such as hospitalization or nutritional support, and the impact on quality of life. The timeline between exposure and documented harm is critical; FAERS data indicate that reports of impaired gastric emptying are among the most frequently reported adverse events for Ozempic, suggesting a temporal association (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). Patients who develop gastroparesis after starting Ozempic may have a stronger claim if symptoms appear during dose escalation or within weeks to months of initiation. In summary, the evidence supports a mechanistic and epidemiological link between Ozempic and gastroparesis. The high frequency of gastrointestinal adverse reactions in clinical trials and the substantial number of FAERS reports of impaired gastric emptying provide a basis for claims. Settlement valuation factors include the adequacy of warnings, the severity of harm, and the temporal relationship between drug exposure and symptom onset. Patients and legal representatives should consider these factors when evaluating potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism. In susceptible individuals, this can lead to gastroparesis, a condition of delayed gastric emptying causing nausea, vomiting, and abdominal pain. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, and the FDA Adverse Event Reporting System has over 2,600 reports of impaired gastric emptying associated with Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).

What factors influence the valuation of an Ozempic gastroparesis claim?

Key factors include the adequacy of warnings (the Ozempic label does not explicitly mention gastroparesis), the severity and duration of symptoms, need for medical interventions like hospitalization, impact on quality of life, and the temporal relationship between Ozempic use and symptom onset. Claims are stronger if symptoms appear during dose escalation or within weeks to months of starting the drug.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.